PARP inhibitors are currently approved by the FDA for treatment of breast and ovarian cancer in the context of germline BRCA mutations and have been previously tested in a phase I study of unselected patients with advanced hematologic malignancies (45). This evidence concerns the gene PARP1 and hematologic disorder.